2002
DOI: 10.1006/gyno.2002.6797
|View full text |Cite
|
Sign up to set email alerts
|

Association between in Vitro Platinum Resistance in the EDR Assay and Clinical Outcomes for Ovarian Cancer Patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
51
1

Year Published

2002
2002
2009
2009

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 82 publications
(52 citation statements)
references
References 16 publications
0
51
1
Order By: Relevance
“…Figure 7A depicts the Kaplan-Meier survival curves for these cases, and demonstrates a clear relationship between the degrees of in vitro resistance seen in the assay and clinical outcome. Konecny et al (2000) and Holloway et al (2001) both reported similar results for newly diagnosed stage III and IV ovarian cancer patients treated with platinum-based chemotherapy after initial cytoreductive surgery. The study of Konecny et al (2000) employed the ATP assay, while Holloway et al (2001) utilized the EDR assay.…”
Section: In Vitro Drug Response and Patient Survivalmentioning
confidence: 66%
See 2 more Smart Citations
“…Figure 7A depicts the Kaplan-Meier survival curves for these cases, and demonstrates a clear relationship between the degrees of in vitro resistance seen in the assay and clinical outcome. Konecny et al (2000) and Holloway et al (2001) both reported similar results for newly diagnosed stage III and IV ovarian cancer patients treated with platinum-based chemotherapy after initial cytoreductive surgery. The study of Konecny et al (2000) employed the ATP assay, while Holloway et al (2001) utilized the EDR assay.…”
Section: In Vitro Drug Response and Patient Survivalmentioning
confidence: 66%
“…Konecny et al (2000) and Holloway et al (2001) both reported similar results for newly diagnosed stage III and IV ovarian cancer patients treated with platinum-based chemotherapy after initial cytoreductive surgery. The study of Konecny et al (2000) employed the ATP assay, while Holloway et al (2001) utilized the EDR assay. These two groups independently found that in vitro resistance to either cisplatin or carboplatin was an adverse factor, with significantly reduced progression-free survival seen in patients with tumors that were resistant to platinum in vitro.…”
Section: In Vitro Drug Response and Patient Survivalmentioning
confidence: 66%
See 1 more Smart Citation
“…In this study, we applied a third-generation in vitro drug response assay to determine if drug resistance patterns for paired synchronous cases were related to the metastatic process and possibly subject to clonal divergence [9,11,12]. Separation of the large number of tumor specimens into primary ovarian and metastatic groups did not uncover any striking differences in chemoresistance profiles for the four agents studied.…”
Section: Discussionmentioning
confidence: 99%
“…Focusing on drug resistance, Holloway et al correlated the clinical outcome of 79 evaluable chemotherapy naïve patients with advanced ovarian cancer to the EDR assay results for cisplatin and carboplatin [11]. In vitro platinum resistance remained an independent predictor of progression-free survival (6 months vs. 24 months) and overall survival (19% vs. 68%) in a multivariate analysis.…”
Section: Discussionmentioning
confidence: 99%